Long-Term Safety of Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from Phase 3 FREEDOMS II Extension Study

被引：0

作者：

Vollmer, Timothy ^{[1
]}

Jeffery, Douglas

Goodin, Douglas ^{[2
]}

Kappos, Ludwig ^{[3
]}

Lublin, Fred ^{[4
]}

Radue, Ernst-Wilhelm ^{[5
]}

Rammohan, Kottil ^{[6
]}

Reder, Anthony ^{[7
]}

Agius, Mark ^{[8
,9
]}

Stites, Tracy ^{[10
]}

Li, Bingbing ^{[10
]}

Cappiello, Linda ^{[11
]}

von Rosenstiel, Philipp ^{[12
]}

Calabresi, Peter ^{[13
]}

机构：

[1] Univ Colorado Denver, Aurora, CO USA

[2] Univ Calif San Francisco, San Francisco, CA 94143 USA

[3] Univ Basel Hosp, CH-4031 Basel, Switzerland

[4] Mt Sinai Med Ctr, Corinne Goldsmith Dickinson Ctr Multiple Sclerosi, New York, NY 10029 USA

[5] Univ Basel Hosp, Med Image Anal Ctr, Basel, Switzerland

[6] Univ Miami, Miami, FL USA

[7] Univ Chicago, Med Ctr, Oak Pk, IL USA

[8] Univ Calif Davis, Davis, CA 95616 USA

[9] VANCHCS, Davis, CA USA

[10] Novartis Pharmaceut, E Hanover, NJ USA

[11] Li Bingbing Bingbing Li Novartis Com, E Hanover, NJ USA

[12] Novartis Pharma AG, Basel, Switzerland

[13] Johns Hopkins Univ Hosp, MS Ctr, Baltimore, MD 21287 USA

来源：

NEUROLOGY | 2013年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P01165

引用

页数：2

共 50 条

[1] Long-term efficacy of fingolimod in patients with relapsing remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study
Reder, A. T.
Jeffery, D.
Goodin, D.
Kappos, L.
Lublin, F. D.
Radue, E. W.
Rammohan, K.
Vollmer, T.
Agius, M. A.
Stites, T.
Li, B.
Cappiello, L.
von Rosenstiel, P.
Calabresi, P. A.
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 510 - 511
[2] Phase III FREEDOMS study extension: long-term safety of fingolimod (FTY720) in relapsing-remitting multiple sclerosis
O'Connor, P.
Polman, C.
Hohlfeld, R.
Selmaj, K.
Olsson, T.
Agoropoulou, C.
Holdbrook, F.
Zhang-Auberson, L.
von Rosenstiel, P.
Kappos, L.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 223 - 223
[3] Long-Term Efficacy and Safety of Fingolimod (FTY720) in Relapsing-Remitting Multiple Sclerosis (RRMS): Results from the Extension of the Phase III FREEDOMS Study
Kappos, Ludwig
Radue, Ernst-Wilhelm
O'Connor, Paul
Polman, Chris
Hohlfeld, Reinhard
Calabresi, Peter
Selmaj, Krzysztof
Agoropoulou, Catherine
Jin, James
Zhang-Auberson, Lixin
Francis, Gordon
NEUROLOGY, 2012, 78
[4] Efficacy and safety of fingolimod versus placebo: primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing-remitting multiple sclerosis
Calabresi, P. A.
Goodin, D.
Jeffery, D.
Kappos, L.
Lublin, F. D.
Rammohan, K.
Reder, A. T.
Vollmer, T.
Agius, M. A.
Cappiello, L.
Stites, T.
Li, B. B.
Malhotra, M.
von Rosenstiel, P.
Radue, E. -W.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 205 - 206
[5] The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis
Derfuss, T.
Sastre-Garriga, J.
Montalban, X.
Rodegher, M.
Wuerfel, J.
Gaetano, L.
Tomic, D.
Azmon, A.
Wolf, C.
Kappos, L.
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2020, 6 (01)
[6] Long-term efficacy and safety of ponesimod: results from randomized phase ii core and extension studies in relapsing-remitting multiple sclerosis
Freedman, M.
Pozzilli, C.
Havrdova, E. Kubala
Coyle, P.
Lemle, A.
Burcklen, M.
Larbalestier, A.
Hennessy, B.
Scherz, T.
Vaclavkova, A.
Olsson, T.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 222 - 222
[7] Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing-remitting multiple sclerosis: results from the phase 3 FREEDOMS II study
Vollmer, T.
Goodin, D.
Jeffery, D.
Kappos, L.
Radue, E. -W.
Rammohan, K.
Reder, A. T.
Agius, M. A.
Cappiello, L.
Stites, T.
Li, B. B.
Malhotra, M.
von Rosenstiel, P.
Calabresi, P. A.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 438 - 439
[8] Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis
Kappos, L.
Li, D.
Calabresi, P.
O'Connor, P.
Bar-Or, A.
Barkhof, F.
Wells, C.
Leppert, D.
Glanzman, R.
Tinbergen, J.
Hauser, S.
JOURNAL OF NEUROLOGY, 2012, 259 : S65 - S65
[9] Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II Trials
Ghezzi, Angelo
Chitnis, Tanuja
K-Laflamme, Annik
Meinert, Rolf
Haering, Dieter A.
Pohl, Daniela
NEUROLOGY AND THERAPY, 2019, 8 (02) : 461 - 475
[10] Effectiveness and safety of long-term fingolimod treatment in relapsing-remitting multiple sclerosis patients with highly active disease
Vorobeychik, G.
Devonshire, V.
Freedman, M. S.
Grand'Maison, F.
Selchen, D.
Schecter, R.
Haddad, P.
Tenenbaum, N.
Bhatt, A.
Pimentel, R.
Kappos, L.
Cohen, J.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 891 - 892

← 1 2 3 4 5 →